Millipore Sigma Vibrant Logo

530587 Proteasome Inhibitor XXIII, PI-1840 - Calbiochem

A cell-permeable, highly potent, selective, and non-covalent inhibitor of chymotrypsin-like (CT-L) activity of 20S proteasome (IC₅₀ = 27 nM).

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: N-Isopropyl-2-(4-propylphenoxy)-N-((3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)methyl)acetamide, PI1840

Primary Target: chymotrypsin-like activity of 20S proteasome
530587
  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      Empirical Formula
      C₂₂H₂₆N₄O₃
      Description
      Overview

      This product has been discontinued.



      A cell-permeable, bioavailable, non-toxic pyridinyl-oxadiazoloisopropylamide compound that acts as a highly potent, selective, and non-covalent inhibitor of chymotrypsin-like (CT-L) activity of 20S proteasome (IC50 = 27 nM). Does not affect tyrpsin-like and postglutamyl-peptide-hydrolysis-like activities of proteasome even at higher concentrations (IC50 >> 100 µM). Its action appears to be readily reversible. Displays over 120-fold greater selectivity for the constitutive proteasome over the immunoproteasome (IC50 = 18 nM vs. 2.17 µM). Induces the accumulation of p27, IκBα and Bax in MDA-MB-468 cells and reduces the viability of a broad spectrum of cancer cells and triggers apoptosis. Shown to increase sensitivity of HCT-116 cells to Nutlin (Cat. No. 444143) by about four- fold, but does not affect p53 -/- HCT-116 cells. Also shown to enhance sensitivity of LNCaP cells to BCl-2 antagonist, BH3-M6 by four-fold, but does not affect DU-145 cells that lack Bax. Suppresses the growth of MDA-MB-231 xenografts in nude mice (150 mg/kg, i.p., q.d.).

      Please note that the molecular weight for this compound is batch-specific due to variable water content.
      Catalogue Number530587
      Brand Family Calbiochem®
      SynonymsN-Isopropyl-2-(4-propylphenoxy)-N-((3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)methyl)acetamide, PI1840
      References
      ReferencesKazi, A., et al. 2014. J. Biol. Chem. 289, 11906.
      Ozcan, S., et al. 2013. J. Med. Chem. 56, 3783.
      Product Information
      FormWhite solid
      Hill FormulaC₂₂H₂₆N₄O₃
      Chemical formulaC₂₂H₂₆N₄O₃
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetchymotrypsin-like activity of 20S proteasome
      Primary Target IC<sub>50</sub>27 nM for chymotrypsin-like (CT-L) activity of 20S proteasome
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      530587 0

      Documentation

      Proteasome Inhibitor XXIII, PI-1840 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      References

      Reference overview
      Kazi, A., et al. 2014. J. Biol. Chem. 289, 11906.
      Ozcan, S., et al. 2013. J. Med. Chem. 56, 3783.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision15-August-2014 JSW
      SynonymsN-Isopropyl-2-(4-propylphenoxy)-N-((3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)methyl)acetamide, PI1840
      DescriptionA cell-permeable pyridinyl-oxadiazoloisopropylamide compound that selectively inhibits 20S proteasome β5 CT-L/chymotrypsin-like over β1 C-L/caspase-like (PGPH-L/postglutamyl-peptide hydrolase-like) activity and β2 T-L/trypsin-like activity (IC50 = 18 nM against CT-L and <100 µM against C-L & T-L activity of rabbit 20S proteasome using 20 µM Suc-LLVY-AMC/Cat. No. 539142, Z-LLE-AMC/Cat. No. 539141, and Bz-VGR-AMC as substrate, respectively; 1 h at 37°C) in a noncovalent and reversible manner, being superior to Bortezomib (Cat. No. 504314) in proteasome selectivity over hematopoietic immunoproteasome (120-fold vs. 2-fold selectivity, respectively, in CT-L assays using rabbit proteasome & immunoproteasome). Culture treatment is shown to result in fast cellular CT-L inhibition (>90% of max inhibition within 10 min in MDA-MB-468; 5 µM), resulting in upregulation of proapoptic p27, IκB-α, Bax, as well as Capase-3 & PARP cleavage with concomitant downregulation of Akt & Survivin and phosphorylation of Akt and S6 (20 µM for 48 h in MDA-MB-468 cultures). Shown to exhibits antiproliferation activity in 12 human cancer cultures (IC50 in 5 d from 2.2 µM/MDA-MB-468 to 45.2 µM/RXF 397 by MTT assay), while being less potent against non-cancer HCA2 fibroblast and MCF-10A mammary epithelial cells ((IC50 in 5 d = 86 & 314 µM, respectively), and selectively enhances Nutlin (Cat. No. 444152) sensitivity in p53+/+, but not p53-/-, HCT-116 cultures. Daily intraperitoneal injection (150 mg/kg/d) is reported to result in 76% retardation of MDA-MB-468-derived tumor growth at the end of a 14 d treatment period among mice in vivo with no apparent weight loss, Bortezomib treatment (1 mg/kg, twice weekly i.p.), in comparison, is reported to result in a loss of 6.21% body weight with no significant tumor growth inhibiton.
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₂₂H₂₆N₄O₃
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (50 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesKazi, A., et al. 2014. J. Biol. Chem. 289, 11906.
      Ozcan, S., et al. 2013. J. Med. Chem. 56, 3783.